Lipoprotein News and Research

RSS

A lipoprotein is a biochemical assembly that contains both proteins and lipids. The lipids or their derivatives may be covalently or non-covalently bound to the proteins.

Resverlogix announces formation of international Clinical Steering Committee for RVX-208 "apabetalone" Phase 3 trial

Resverlogix Corp. is pleased to announce the formation of an international Clinical Steering Committee for the RVX-208 "apabetalone" Phase 3 clinical trial BETonMACE assessing major adverse cardiac events (MACE) in high-risk vascular patients with diabetes mellitus and a recent Acute Coronary Syndrome event. BETonMACE is expected to start in the fall of 2015.

4 Aug 2015

FDA approves Praluent (alirocumab) Injection for treatment of patients with high LDL cholesterol

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration approved Praluent (alirocumab) Injection, the first FDA-approved treatment in a new class of drugs known as PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors.

25 Jul 2015

EMA's CHMP recommends approval of Praluent (alirocumab) for use in patients with hypercholesterolemia

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the European Medicine Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion for the marketing authorization of Praluent (alirocumab), recommending its approval for use in certain adult patients with hypercholesterolemia.

24 Jul 2015

Study examines accuracy, cost-effectiveness of new cholesterol guidelines in identifying increased CVD risk

An examination of the 2013 guidelines for determining statin eligibility, compared to guidelines from 2004, indicates that they are associated with greater accuracy and efficiency in identifying increased risk of cardiovascular disease (CVD) events and presence of subclinical coronary artery disease, particularly in individuals at intermediate risk, according to a study in the July 14 issue of JAMA.

15 Jul 2015

$Wayne State researchers explore effects of Tocotrienol-rich fraction from palm oil in ESRD patients$

Wayne State researchers explore effects of Tocotrienol-rich fraction from palm oil in ESRD patients

End-stage renal disease (ERSD) is the last stage of chronic kidney disease where the kidneys function at under 10 to 15 percent of their normal capacity. At this stage, kidneys cannot effectively remove waste or excess fluid from the blood system, and dialysis or a kidney transplant is necessary to live.

14 Jul 2015

Virginia Tech researchers develop new scoring method for assessing overall beverage intake quality

Researchers at Virginia Tech have developed a new scoring method for assessing beverage intake, the Healthy Beverage Index (HBI). In a report published in the Journal of the Academy of Nutrition and Dietetics they describe how this tool can be used to more accurately evaluate dietary consumption of all types of fluids.

10 Jul 2015

Phase 3 ODYSSEY JAPAN trial of Praluent injection meets primary endpoint

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the Phase 3 ODYSSEY JAPAN trial of the investigational therapy Praluent® (alirocumab) Injection met its primary endpoint.

9 Jul 2015

Darapladib shows promise in diabetic macular oedema

Placebo-controlled trial findings show that lipoprotein-associated phospholipase A2 inhibition modestly benefits the vision of patients with centre-involved diabetic macular oedema and warrants further investigation.

8 Jul 2015

Akcea Therapeutics obtains FDA Orphan Drug Designation for volanesorsen

Akcea Therapeutics, a wholly-owned subsidiary of Isis Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation to volanesorsen (ISIS-APOCIIIRx) for the treatment of patients with Familial Chylomicronemia Syndrome (FCS).

6 Jul 2015

Tree nut consumption associated with lower body weight and lower risk of obesity

In a study published this week in Nutrition Journal*, researchers compared risk factors for heart disease and metabolic syndrome of tree nut consumers versus those who did not consume tree nuts. Tree nut (almonds, Brazil nuts, cashews, hazelnuts, macadamias, pecans, pine nuts, pistachios and walnuts) consumption was associated with lower body mass index (p=0.004), systolic blood pressure (p=0.001), insulin resistance (p=0.043) and higher levels of high-density lipoprotein-cholesterol (good cholesterol) (p=0.022).

30 Jun 2015

Omega-3 Coalition forms scientific advisory council to educate consumers about benefits, safety of omega-3s

The Omega-3 Coalition, a group of industry stakeholders working to improve consumer knowledge of omega-3s, today announced the formation of a scientific advisory council.

25 Jun 2015

Nutrition experts offer tips to employees working in sedentary environment

When it comes to taking a physical activity break at work, it's more about the frequency than duration. That's advice Kansas State University experts in human nutrition and kinesiology are offering to employees working in a sedentary environment who are looking to improve their health.

24 Jun 2015

DCRI announces new study to better understand lipid management

At a time when lipid management in the United States is undergoing transition in response to new guideline recommendations and expanding lipid-lowering therapy options, the Duke Clinical Research Institute (DCRI) today announced a new study to better understand contemporary lipid management as well as the beliefs and attitudes of patient and providers regarding cholesterol, cardiovascular risk assessment, and options for lipid treatments.

17 Jun 2015

Dietary compounds in milk-based products may protect against cardiovascular risk

The Maillard reaction is a chemical reaction between amino acids and reducing sugars that results in browned foods like seared steaks and toasted bread. When proteins and sugars are mixed together and heated, new chemical compounds are formed. Some are responsible for new flavors and some, according to a new study published in the Journal of Dairy Science, may protect us against cardiovascular disease.

11 Jun 2015

Amgen to discuss data supporting Repatha BLA for high cholesterol treatment with FDA EMDAC

Amgen today announced that the Company will discuss the data supporting the Repatha (evolocumab) Biologics License Application (BLA) for the treatment of high cholesterol with the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC).

10 Jun 2015

FDA's Advisory Committee recommends approval of Praluent (alirocumab) Injection

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration recommended the approval of the investigational therapy Praluent (alirocumab) Injection.

9 Jun 2015

People who have higher HDL function experience fewer heart attacks later in life

HDL is the 'good cholesterol' that helps remove fat from artery walls, reversing the process that leads to heart disease. Yet recent drug trials and genetic studies suggest that simply pushing HDL levels higher doesn't necessarily reduce the risk of heart disease.

27 May 2015

Simple blood test could help predict effectiveness of interferon-based therapy in HCV-infected patients

A simple blood test can be used to predict which chronic hepatitis C patients will respond to interferon-based therapy, according to a report in the May issue of Cellular and Molecular Gastroenterology and Hepatology, the basic science journal of the American Gastroenterological Association.

13 May 2015

Enrollment begins for first major cardiovascular prevention trial for people infected with HIV

The first clinical trial to investigate whether treatment with a statin drug can reduce the increased cardiovascular disease risk in people infected with HIV has begun enrolling patients. Based at Massachusetts General Hospital, the six-year, $40 million REPRIEVE (Randomized Study to Prevent Vascular Events in HIV) trial will be conducted at around 100 sites in the U.S., Canada, Puerto Rico and Thailand with funding from the National Heart, Lung, and Blood Institute in collaboration with the AIDS Clinical Trials Group and support from the National Institutes of Allergy and Infectious Diseases.

24 Apr 2015

Sugar-sweetened beverages increase risk factors for cardiovascular disease

Beverages sweetened with low, medium and high amounts of high-fructose corn syrup significantly increase risk factors for cardiovascular disease, even when consumed for just two weeks by young, healthy men and women, reports a team of researchers at the University of California, Davis.

23 Apr 2015

Lipoprotein News and Research

Further Reading

Resverlogix announces formation of international Clinical Steering Committee for RVX-208 "apabetalone" Phase 3 trial

FDA approves Praluent (alirocumab) Injection for treatment of patients with high LDL cholesterol

EMA's CHMP recommends approval of Praluent (alirocumab) for use in patients with hypercholesterolemia

Study examines accuracy, cost-effectiveness of new cholesterol guidelines in identifying increased CVD risk

Wayne State researchers explore effects of Tocotrienol-rich fraction from palm oil in ESRD patients

Virginia Tech researchers develop new scoring method for assessing overall beverage intake quality

Phase 3 ODYSSEY JAPAN trial of Praluent injection meets primary endpoint

Darapladib shows promise in diabetic macular oedema

Akcea Therapeutics obtains FDA Orphan Drug Designation for volanesorsen

Tree nut consumption associated with lower body weight and lower risk of obesity

Omega-3 Coalition forms scientific advisory council to educate consumers about benefits, safety of omega-3s

Nutrition experts offer tips to employees working in sedentary environment

DCRI announces new study to better understand lipid management

Dietary compounds in milk-based products may protect against cardiovascular risk

Amgen to discuss data supporting Repatha BLA for high cholesterol treatment with FDA EMDAC

FDA's Advisory Committee recommends approval of Praluent (alirocumab) Injection

People who have higher HDL function experience fewer heart attacks later in life

Simple blood test could help predict effectiveness of interferon-based therapy in HCV-infected patients

Enrollment begins for first major cardiovascular prevention trial for people infected with HIV

Sugar-sweetened beverages increase risk factors for cardiovascular disease

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics